Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study

Abstract

Background

In the OSST study, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who switched from long-term entecavir (ETV) therapy to pegylated interferon-α2a (PEG-IFN-α2a; 40 kDa) achieved higher rates of HBeAg seroconversion and hepatitis B surface antigen (HBsAg) loss than those who continued ETV. Herein we report the sustainability of serological responses during 1 year of untreated follow-up in patients who switched from ETV to PEG-IFN-α2a therapy.

Methods

A total of 62 patients who completed 48 weeks of PEG-IFN-α2a therapy were followed-up for 48 weeks off treatment. Primary end points were HBeAg seroconversion and maintenance of HBeAg seroconversion at 48 weeks post-treatment. Secondary end points included HBsAg loss, HBV DNA <1,000 copies/ml and alanine aminotransferase normalization (<1 x upper limit of normal).

Results

The HBeAg seroconversion rate increased from 17.7% (11/62) at the end of treatment to 38.7% (24/62) 1 year post-treatment. Sustained HBeAg seroconversion was achieved by 63.6% (7/11) patients with end-of-treatment responses, while late HBeAg seroconversion was achieved by 33.3% (17/51) of patients who did not have end-of-treatment responses. Sustained HBsAg loss was documented in 6 of 7 patients, and sustained HBV DNA suppression was achieved in 60% (27/45) of patients with an end-of-treatment response.

Conclusions

In patients who do not achieve HBeAg sero-conversion during long-term ETV therapy, switching to finite treatment with PEG-IFN-α2a produces HBeAg sero-conversion in a substantial proportion of patients at end of treatment and during 1 year of follow-up. Moreover, HBeAg seroconversion and HBsAg loss are sustained in most patients during 1 year of untreated follow-up.

References

European Association for the Study of the Liver.

EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection.

J Hepatol 2012; 57: 167–185.

Chen

Y.C.

, Sheen

I.S.

, Chu

C.M.

, Liaw

Y.F.

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.

Gastroenterology 2002; 123: 1084–1089.

Liaw

Y.F.

, Kao

J.H.

, Piratvisuth

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Hepatol Int 2012; 6: 531–561.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B: update 2009.

Hepatology 2009; 50: 661–662.

Lau

G.K.

Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.

Liver Int 2010; 30: 512–520.

Chu

C.M.

, Liaw

Y.F.

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up.

Hepatology 2007; 45: 1187–1192.

Sonneveld

M.J.

, Janssen

H.L.

Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?

Liver Int 2011; 31: 78–84.

Janssen

H.L.

, van Zonneveld

, Senturk

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Lancet 2005; 365: 123–129.

Chang

T.T.

, Gish

R.G.

, de Man

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

N Engl J Med 2006; 354: 1001–1010.

10.

Lai

C.L.

, Chien

R.N.

, Leung

N.W.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group 1 2647.

N Engl J Med 1998; 339: 61–68.

11.

Lai

C.L.

, Gane

, Liaw

Y.F.

Telbivudine versus lamivudine in patients with chronic hepatitis B.

N Engl J Med 2007; 357: 2576–2588.

12.

Lau

G.K.

, Piratvisuth

, Luo

K.X.

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

N Engl J Med 2005; 352: 2682–2695.

13.

Dienstag

J.L.

, Schiff

E.R.

, Wright

T.L.

Lamivudine as initial treatment for chronic hepatitis B in the United States.

N Engl J Med 1999; 341: 1256–1263.

14.

Marcellin

, Chang

T.T.

, Lim

S.G.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

N Engl J Med 2003; 348: 808–816.

15.

Marcellin

, Heathcote

E.J.

, Buti

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

N Engl J Med 2008; 359: 2442–2455.

16.

Moucari

, Korevaar

, Lada

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.

J Hepatol 2009; 50: 1084–1092.

17.

Marcellin

, Bonino

, Yurdaydin

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.

Hepatol Int 2013; 7: 88–97.

18.

Reijnders

J.G.

, Perquin

M.J.

, Zhang

, Hansen

B.E.

, Janssen

H.L.

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

Gastroenterology 2010; 139: 491–498.

19.

Liaw

Y.F.

, Chu

C.M.

Hepatitis B virus infection.

Lancet 2009; 373: 582–592.

20.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B.

Hepatology 2007; 45: 507–539.

21.

Liaw

Y.F.

, Leung

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Hepatol Int 2008; 2: 263–283.

22.

Liaw

Y.F.

, Jia

J.D.

, Chan

H.L.

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

Hepatology 2011; 54: 1591–1599.

23.

Piratvisuth

, Lau

, Chao

Y.C.

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B 1.

Hepatol Int 2008; 2: 102–110.

24.

Niederau

, Heintges

, Lange

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.

N Engl J Med 1996; 334: 1422–1427.

25.

van Zonneveld

, Honkoop

, Hansen

B.E.

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

Hepatology 2004; 39: 804–810.

26.

European Association for the Study of the Liver.

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

J Hepatol 2009; 50: 227–242.

27.

Song

M.J.

, Song do

, Kim

H.Y.

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.

World J Gastroenterol 2012; 18: 6277–6283.

28.

Ning

, Wu

, Han

[Difficult-to-treat chronic hepatitis B].

Infec Dis Info 2011; 24: 65–67. Chinese.

29.

Ning

, Han

, Sun

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

J Hepatol 2014; 61: 777–784.

30.

Lau

G.K.K.

, Piratvisuth

, Luo

K.X.

Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B.

J Hepatol 2006; 44: S23.

31.

Buster

E.H.

, Schalm

S.W.

, Janssen

H.L.

Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t) ide analogues.

Best Pract Res Clin Gastroenterol 2008; 22: 1093–1108.

32.

Piratvisuth

, Marcellin

, Popescu

, Kapprell

H.P.

, Rothe

, Lu

Z.M.

Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.

Hepatol Int 2013; 7: 429–436.

33.

Sonneveld

M.J.

, Hansen

B.E.

, Piratvisuth

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

Hepatology 2013; 58: 872–880.